KV7 channelopathies

Pflugers Arch. 2010 Jul;460(2):277-88. doi: 10.1007/s00424-010-0831-3. Epub 2010 Apr 18.


KV7 voltage-gated potassium channels, encoded by the KCNQ gene family, have caught increasing interest of the scientific community for their important physiological roles, which are emphasized by the fact that four of the five so far identified members are related to different hereditary diseases. Furthermore, these channels prove to be attractive pharmacological targets for treating diseases characterized by membrane hyperexcitability. KV7 channels are expressed in brain, heart, thyroid gland, pancreas, inner ear, muscle, stomach, and intestines. They give rise to functionally important potassium currents, reduction of which results in pathologies such as long QT syndrome, diabetes, neonatal epilepsy, neuromyotonia, or progressive deafness. Here, we summarize some key traits of KV7 channels and review how their molecular deficiencies could explain diverse disease phenotypes. We also assess the therapeutic potential of KV7 channels; in particular, how the activation of KV7 channels by the compounds retigabine and R-L3 may be useful for treatment of epilepsy or cardiac arrhythmia.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Carbamates / pharmacology
  • Channelopathies / genetics
  • Channelopathies / physiopathology*
  • Epilepsy / drug therapy
  • Epilepsy / genetics
  • Humans
  • KCNQ Potassium Channels / agonists
  • KCNQ Potassium Channels / drug effects
  • KCNQ Potassium Channels / genetics*
  • KCNQ Potassium Channels / physiology*
  • Long QT Syndrome / genetics
  • Mutation
  • Phenylenediamines / pharmacology


  • Carbamates
  • KCNQ Potassium Channels
  • Phenylenediamines
  • ezogabine